Now trading at a price of $42.65, Ionis Pharmaceuticals has moved -1.0% so far today.
Ionis Pharmaceuticals returned losses of -7.6% last year, with its stock price reaching a high of $50.43 and a low of $23.95. Over the same period, the stock underperformed the S&P 500 index by -24.3%. AThe company's 50-day average price was $40.18. Ionis Pharmaceuticals, Inc., a commercial-stage biotechnology company, provides RNA-targeted medicines in the United States. Based in Carlsbad, CA, the Mid-Cap Health Care company has 1,069 full time employees. Ionis Pharmaceuticals has not offered a dividend during the last year.
The Business Is Unprofitable and Its Balance Sheet Is Highly Leveraged:
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|
| Revenue (k) | $1,122,599 | $729,264 | $810,456 | $587,367 | $787,647 | $705,138 |
| Operating Margins | 33% | -24% | -4% | -70% | -45% | -67% |
| Net Margins | 25% | -61% | -4% | -46% | -47% | -64% |
| Net Income (k) | $278,143 | -$444,263 | -$28,597 | -$269,722 | -$366,286 | -$453,897 |
| Net Interest Expense (k) | $12,440 | $9,510 | $9,349 | $8,122 | $12,660 | $16,994 |
| Depreciation & Amort. (k) | $12,540 | $13,365 | $15,487 | $14,328 | $10,292 | $9,614 |
| Diluted Shares (k) | 153,303 | 139,612 | 160,340 | 141,848 | 143,190 | 149,514 |
| Earnings Per Share | $1.9 | -$3.18 | -$0.2 | -$1.9 | -$2.56 | -$3.04 |
| EPS Growth | n/a | -267.37% | 93.71% | -850.0% | -34.74% | -18.75% |
| Avg. Price | $64.97 | $54.17 | $40.86 | $35.3 | $50.59 | $43.1 |
| P/E Ratio | 32.48 | -17.03 | -204.3 | -18.58 | -19.76 | -14.18 |
| Free Cash Flow (k) | $314,722 | $772 | $18,844 | -$290,091 | -$331,318 | -$546,227 |
| CAPEX (k) | $30,905 | $35,120 | $11,955 | $15,721 | $23,805 | $45,280 |
| EV / EBITDA | 24.03 | -48.41 | -336.5 | -14.95 | -23.7 | -15.67 |
| Total Debt (k) | $785,500 | $539,112 | $59,713 | $1,194,233 | $1,308,360 | $1,253,062 |
| Current Ratio | 9.97 | 3.56 | 9.75 | 7.07 | 5.9 | 8.47 |
Ionis Pharmaceuticals has declining EPS growth, negative cash flows, and High Levels of Debt. On the other hand, the company has an excellent current ratio of 8.47 working in its favor. Furthermore, Ionis Pharmaceuticals has declining revenues and increasing reinvestment in the business.
Ionis Pharmaceuticals does not have a meaningful trailing P/E ratio since its earnings per share are negative. Its forward EPS guidance is negative too, at $-3.74. The average P/E ratio for the Health Care sector is 22.94. Furthermore, Ionis Pharmaceuticals is likely overvalued compared to the book value of its equity, since its P/B ratio of 10.75 is higher than the sector average of 3.19.
Ionis Pharmaceuticals Has an Average Rating of Buy:
The 26 analysts following Ionis Pharmaceuticals have set target prices ranging from $38.0 to $83.0 per share, for an average of $58.23 with a buy rating. The company is trading -26.8% away from its average target price, indicating that there is an analyst consensus of strong upside potential.
Ionis Pharmaceuticals has an above average percentage of its shares sold short because 9.6% of the company's shares are sold short. Institutions own 107.8% of the company's shares, and the insider ownership rate stands at 0.78%, suggesting a small amount of insider investors. The largest shareholder is FMR, LLC, whose 15% stake in the company is worth $1,007,119,436.
